⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 12, 2026Bioconjugate Chemistry

Development of Novel Cholecystokinin 2 Receptor-Targeted Radioligand Containing Albumin Binder for Efficient ¹¹¹ In/ ¹⁷⁷ Lu Theranostics

Takahiro Yamamoto Kazuma Nakashima Nobuki Kazuta Hiroyuki Watanabe Masahiro Ono

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to develop a new radioligand that specifically targets the cholecystokinin 2 receptor (CCK2R) for cancer therapy.
Developed Lu-MGS5-DA as a radiotheranostic pair targeting CCK2R-expressing cancers.
Conducted preclinical evaluations to assess effectiveness and binding affinity of the new radioligand.
Demonstrated significant tumor targeting in CCK2R-expressing cancer models.
Showed improved therapeutic outcomes compared to existing treatments.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Lu]Lu-MGS5-DA is a promising radiotheranostic pair for the treatment of CCK2R-expressing cancers.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yamamoto et al. (2026) studied this question.

synapsesocial.com/papers/6a2e4779b1cc60ccdea8c03b https://doi.org/10.1021/acs.bioconjchem.6c00272

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive CancersIn Vitro Study · 2023 · 9 citations
2Synthesis and in vitro evaluation of pharmacokinetically optimized 99mTc-labeled cholecystokinin-2 receptor-targeted peptides for improved SPECT imagingIn Vitro Study · 2026
3Peptide receptor radionuclide therapy targeting the cholecystokinin-2 receptor: Preclinical and first clinical experience in small cell lung cancer2025
4Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung CancerOriginal Research · 2026 · 2 citations
5CCKBR (Gastrin Receptor) as a Theranostic Target in Oncology: Biological Rationale, Diagnostic Imaging, and Next-Generation Peptide-Based Drug DevelopmentReview · 2026

Biodistribution and Radiation Dosimetry for 68Ga-DOTA-CCK-66, a Novel CCK2R-Targeting Compound for Imaging of Medullary Thyroid Cancer2024
Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation2025
Development of an Optimized CXCR4-Targeting Theranostic Pair2026
Smart Gold Nanoprobe for CT Imaging of Granzyme-B Activity: towards Early Immunotherapy Response MonitoringBioconjugate Chemistry · 2026
Hetero-Cross-Linking of Peptides Enabled by Solvent-Regulated Diazo-Type Esterification of Carboxylic AcidsBioconjugate Chemistry · 2026

More from Bioconjugate Chemistry

More from Kyoto University